Game changing medicines to save Australian cancer patients up to $150,000
Australians living with non-small cell lung cancer and early stage acute lymphoblastic leukaemia will soon be able to access better treatment, thanks to two significant amendments to the Pharmaceutical Benefits Scheme. From December 1, more than 2,200 patients with metastatic non-small cell lung cancer will be able to access Keytruda® (pembrolizumab) as a first line…
